Commentary: Statins and fracture - Why the confusion?

International Journal of Epidemiology

Volumn 35, Issue 5, 2006, Pages 1312-1313

  Edwards, C J ^a,b   Arden, N K ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PRAVASTATIN;

BONE DENSITY; BONE MINERAL; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG USE; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; MEDICAL DECISION MAKING; NOTE; OBSERVATIONAL STUDY; OSSIFICATION; PHYSICAL ACTIVITY; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK REDUCTION; SOCIOECONOMICS;

DRUG ADMINISTRATION SCHEDULE; FRACTURES, BONE; HIP FRACTURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RESEARCH DESIGN; SELECTION BIAS;

EID: 33750215530     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyl137     Document Type: Note

References (9)

1. Mundy G, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-49.
2. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000;355:2218-19.
3. Bauer DC, Mundy GR, Jamal SA et al. Use of statins and fracture: Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004;164:146-52.
4. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10.
5. van Staa TP, Wegman S, de VF, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001;285:1850-55.
6. de Vries F, de Vries C, Cooper C, Leufkens B, van Staa T-P. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: The General Practice Research Database. Int J Epidemiol 2006;35:1301-08.
7. Pedersen AT, Ottesen B. Issues to debate on the Women's Health Initiative (WHI) study. Epidemiology or randomized clinical trials - time out for hormone replacement therapy studies? Hum Reprod 2003;18:2241-44.
8. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
9. Reid IR, Hague W, Emberson J et al. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001;357:509-12.